Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio

Reuters

2025/08/25

Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio

Aditxt, Inc., a company known for accelerating promising health innovations, has provided an update on its wholly owned subsidiary, Adimune, Inc. Adimune is pioneering a DNA-based therapeutic platform aimed at reprogramming the immune system. With a strong intellectual property portfolio consisting of 96 granted and 22 pending patents, Adimune is strategically positioned to address the global autoimmune therapeutics market, projected to exceed $160 billion by 2030. The company plans to seek FDA submission for first-in-human trials targeting type 1 diabetes and stiff person syndrome by early 2026. Adimune's platform seeks to restore immune tolerance without chronic immunosuppression, potentially transforming treatment approaches for conditions like type 1 diabetes, psoriasis, and stiff person syndrome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250825106664) on August 25, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2562242618"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562242618\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562242618?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562242618","market":"us","top_or_hot":-1,"title":"Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aditxt, Inc., a company known for accelerating promising health innovations, has provided an update on its wholly owned subsidiary, Adimune, Inc. Adimune is pioneering a DNA-based therapeutic platform aimed at reprogramming the immune system. With a strong intellectual property portfolio consisting of 96 granted and 22 pending patents, Adimune is strategically positioned to address the global autoimmune therapeutics market, projected to exceed $160 billion by 2030. The company plans to seek FDA submission for first-in-human trials targeting type 1 diabetes and stiff person syndrome by early 2026. Adimune's platform seeks to restore immune tolerance without chronic immunosuppression, potentially transforming treatment approaches for conditions like type 1 diabetes, psoriasis, and stiff person syndrome.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250825106664) on August 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-25 21:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aditxt, Inc., a company known for accelerating promising health innovations, has provided an update on its wholly owned subsidiary, Adimune, Inc. Adimune is pioneering a DNA-based therapeutic platform aimed at reprogramming the immune system. With a strong intellectual property portfolio consisting of 96 granted and 22 pending patents, Adimune is strategically positioned to address the global autoimmune therapeutics market, projected to exceed $160 billion by 2030. The company plans to seek FDA submission for first-in-human trials targeting type 1 diabetes and stiff person syndrome by early 2026. Adimune's platform seeks to restore immune tolerance without chronic immunosuppression, potentially transforming treatment approaches for conditions like type 1 diabetes, psoriasis, and stiff person syndrome.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250825106664) on August 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADTX","symbol_name":"ADiTx Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nNDLb9mb6D:1","article_id":"2562242618","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562242618","pubTimestamp":1756127723,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aditxt, Inc., a company known for accelerating promising health innovations, has provided an update on its wholly owned subsidiary, Adimune, Inc. Adimune is pioneering a DNA-based therapeutic platform aimed at reprogramming the immune system. With a strong intellectual property portfolio consisting of 96 granted and 22 pending patents, Adimune is strategically positioned to address the global autoimmune therapeutics market, projected to exceed $160 billion by 2030. The company plans to seek FDA submission for first-in-human trials targeting type 1 diabetes and stiff person syndrome by early 2026. Adimune's platform seeks to restore immune tolerance without chronic immunosuppression, potentially transforming treatment approaches for conditions like type 1 diabetes, psoriasis, and stiff person syndrome.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADTX":"ADiTx Therapeutics","BK4139":"生物科技"},"translate_title":"ADiTx Inc.的子公司Adimune凭借强大的专利组合推进免疫系统重编程","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADTX":0.9},"content_text":"Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio\n    \n\n        Aditxt, Inc., a company known for accelerating promising health innovations, has provided an update on its wholly owned subsidiary, Adimune, Inc. Adimune is pioneering a DNA-based therapeutic platform aimed at reprogramming the immune system. With a strong intellectual property portfolio consisting of 96 granted and 22 pending patents, Adimune is strategically positioned to address the global autoimmune therapeutics market, projected to exceed $160 billion by 2030. The company plans to seek FDA submission for first-in-human trials targeting type 1 diabetes and stiff person syndrome by early 2026. Adimune's platform seeks to restore immune tolerance without chronic immunosuppression, potentially transforming treatment approaches for conditions like type 1 diabetes, psoriasis, and stiff person syndrome.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250825106664) on August 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}